readthroughSign in
Oct 1, 2026Trial updateUpdated

Oncolytics reports faster enrollment in REO 033 colorectal cancer study

Nearly all Part A sites are active, an interim update is expected by year-end 2026, and the FDA has aligned on a possible accelerated approval route.

Oncolytics Biotech Inc. (Nasdaq: ONCY) said on September 28, 2026 that nearly all planned clinical sites for Part A of REO 033 have now been activated, and multiple patients are currently enrolled.1 The company said that with site activation largely finished, it is focused on accelerating enrollment and generating randomized clinical data evaluating the contribution of pelareorep to the current standard-of-care regimen.1

The study evaluates pelareorep in combination with folinic acid, fluorouracil and irinotecan ("FOLFIRI") and bevacizumab versus FOLFIRI and bevacizumab in patients with second-line RAS-mutant MSS mCRC.1 Part A is expected to enroll approximately 60 patients randomized between the two treatment arms, with objective response rate ("ORR") as the primary endpoint, and progression-free survival ("PFS"), overall survival ("OS"), safety, and biomarker analyses among the additional endpoints.1

Chief Operating Officer John McAdory said the company expects to have the ability to report interim data from Part A by year-end, based on the number of evaluable patients enrolled by the end of October.1

The design builds on an earlier, non-randomized study, REO 022, in which pelareorep in combination with FOLFIRI and bevacizumab demonstrated encouraging ORR, PFS, and OS compared with historical second-line benchmarks, including a 33% objective response rate, median progression-free survival of 16.6 months, and median overall survival of 27.0 months, versus historical benchmarks of roughly 6-11% ORR, 5.7 months PFS, and 11.2 months OS.1 The company noted the REO 022 results were generated in a small, non-randomized study, and cross-study comparisons have inherent limitations.1

Oncolytics also said it recently aligned with the FDA on the concept for a potential pivotal Part B expansion of REO 033.1 Under that proposed approach, a Part B stage would extend from the ongoing randomized study and could potentially support an accelerated approval filing tied to tumor response rate, with progression-free survival data underpinning a possible full approval. The company said it expects data from Part A to inform the final size and execution of the potential pivotal Part B expansion.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.